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Objectives. This study was conducted to explore mechanisms
that could explain the possible clinical benefit dearly administra-
tion of a beta,-selective adrenoreceptor blocking agent or a
bradycardiac drug as adjunct to thrombolysis in acute myocardial
infarction .
Beckgrowid. The effects of beta-blockers given concomitantly
with thrombolytic therapy in patients with acute myocardial
infarction have not been fully examined . The potential rule of
specific bradycardlac agents lacking negative inotropism as an
alternative to beta-Mockers in this setting has never been studied
in humans.
Methods . In a double-blinL study, we examined the effects of
early intravenous and continued oral ad,ninistretion of a beta-
blocker (atenolol), a specific bradycardlac agent (alfnidine) or
placebo on left ventricular function, late coronary artery patency,
infarct size, exercise capacity and incidence of arrhythmias .
Results. A total of 292 patients with acute myocardial infarc-
tion of s5 h duration and without contraindications to thrombo-
lytic or beta-blocker therapy were studied . Of these, 140 were
allocated to treatment with atenolol (5 to 10 mg intravenously
In the prethrombolytic era, early use of intravenous beta-
selective adrenoreceptor blocking agents was shown to
reduce mortality . Pooled data from 27 trials in approximately
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followed by 25 to 50 mg orally every 12 h), 98 to alfnidine (20 to
40 mg intravenously followed by 20 to 40 mg orally every 8 h) and
94 to placebo . All patients received 100 mg of alteplase over 3 h
and full intravenous heparinization . No significant differences in
coronary artery patency, global ejection fraction or regional wall
motion were observed at 10 to 14 days among the three groups .
Likewise, enzymatic and scintigraphic infarct size were also very
similar. Neither atenolol nor alinidine was associated with a
significant reduction in the incidence of arrhythmias during the
1st 24 h . No significant differences In clinical events were ob-
served, with the exception of a greater incidence of nonfatal
pulmonary edema in the atenolol group (6% vs . 1% in the
alinidine group and 0% in the placebo group, p = 0 .021) .
Conclusions. In the absence of contraindications, the adminis-
tration of a beta-blocker or a specific bradycardiac agent together
with thrombolytic therapy was safe . In this limited number of
patients, these agents did not appear to esthonce myocardial
r.alvage or preservation of left ventricular function or to reduce the
incidence of major arrhythmias in the early phase of infarction .
(I Am Call Cardiol 1993;22:407-16)
27,000 patients treated with these agents revealed a 13%
reduction in early mortality (1) . When these agents have
been given in combination with thrombolytic therapy, con-
flicting results have been obtained . Although most animal
studies (2-6) demonstrated enhanced myocardial salvage,
most (2-4) also failed to demonstrate a persistent beneficial
effect on left ventricular function . In an open study in 54
successfully reperfused patients, Grines et al . (7) reported
improved motion of the infarct zone immediately after
intravenous beta-blockade without an effect on global func-
tion . In
the large, randomized Thrombolysis in Myocardial
Infarction (TIMi) Phase Ii-B trial (8).
early beta-blockade
with metopro(ol did not improve left ventricular function or
survival despite less recurrent ischemia and reinfarction in
the 1st week
. A much smaller French pilot trial (9) also failed
to demonstrate an effect on left ventricular function of
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another beta s
-selective blocker, atenolol, given in combina-
tion with streptokinase . The effects of concomitant beta-
blockade on coronary artery patency, infarct size, arrhyth-
mias and exercise capacity before hospital discharge are
largely unknown and have never been studied in a prospec-
tive randomized trial .
Betablockers produce a negative isotropic effect and
might be harmful in patients with acute myocardial infarction
and severely depressed left ventricular function . It has been
shown (10) that specific bradycardiac agents can attenuate
exercise-induced ischemic dysfunction and improve regional
perfusion without compromising regional contractile func-
tion of nonischemic areas or global left ventricular function.
Furthermore, it has been demonstrated by Guth et al . (11)
that the beneficial effects of cardioselective beta-blockade on
exercised-induced ischemia are due entirely to negative
chronotropism. Therefore, these agents may constitute an
attractive alternative to betablockers in the setting of acute
myocardial infarction. To date, they have never been studied
in this context.
The present study in patients with acute myocardial
infarction was designed to determine whether early admin-
istration of a betablocker or a specific bradycardiac agent
was more effective than placebo in limiting infarct size and
preserving left ventricular function . In addition, we evalu-
ated other possible mechanisms that could explain the sup-
posed clinical benefit of these agents as adjunctive treatment
to thrombolysis .
Methods
Patient selection. In participating centers (see Appendix),
patients <71 years of age with chest pain suggestive of acute
myocardial infarction lasting >30 min were considered for
enrollment if they met the following inclusion criteria: 1) ST
segment elevation of 0.2 mV in two or more limb leads or
leads Vs and V6 or 0.3 mV in two or more precordial leads
(V 1 to V4 ) or ST elevation of 0 .1 mV in two leads (II, III,
aVF or Vs and V6) associated with ST depression of 0.2 mV
in two precordial leads, suggesting posterior wall infarction;
2)' onset of chest pain <5 h before initiation of therapy ; 3) no
previous history of angioplasty or bypass surgery ; 4) no
contraindications to thrombolytic therapy ; 5) no intake of a
beta-blocker or calcium antagonist in the week preceding the
onset of infarction; and 6) no contraindications for acute
intravenous administration of beta-blockers . The following
were considered
contraindications
for such agents: heart
rate persistently <50 beats/min, systolic blood pressure
persistently <90 min Hg, clinical signs of overt heart failure
or cardiogenic shock, second- or third-degree atrioventricu-
lar (AV) block and history of bronchospasin or sick sinus
syndrome .
Randomisation and concomitant treatment. With the use
of a double-dummy technique, eligible patients were ran-
domized to one of the following study treatments : 1) a
betas
-selective adrenoreceptor blocker, atenolol (5 mg intra-
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venously over 5 min repeated after 10 min by a second dose
• 5 mg if heart rate and systolic blood pressure did not
decrease to <60 beatsimin and <90 mm Hg, respectively) ;
2) a specific bradycardiac agent, alinidine (N-allyl derivative
• clonidine) [121 ; 20 mg intravenously over 5 min, eventu-
ally followed by a second dose of 20 mg [same criteria as for
atenololl) ; 3) placebo (one or two intravenous injections) .
Oral treatment (25 to 50 mg of atenolol every 12 h, 20 to
40 mg of alinidine every 8 h or placebo) was continued for 10
to 14 days and stopped on the evening before the technical
examinations. The first oral dose was given immediately
after the intravenous dose if heart rate and systolic blood
pressure did not decrease to <60 beats/min and <90 mm Hg,
respectively. In contrast, if heart rate and systolic blood
pressure were <40 beats/min and <90 mm Hg after the first
or second intravenous dose, the first oral administration was
postponed for 8 to 12 h .
Study medication was started first and followed as soon
as possible by thrombolytic therapy (100 mg of alteplase
over 3 h) and heparin (5,000 IU bolus injection followed by
continuous infusion of 1,000 lU/h until angiography) . Be-
cause this study was designed and accepted by the investi-
gators before the first public presentation of the Second
International Study of Infarct Survival (ISIS)-2 Trial (at the
37th Annual Scientific Sessions of the American College of
Cardiology, Atlanta, Georgia, March 1988) and because
intravenous heparin was continued throughout the hospital
stay, aspirin was not given. In addition, the level of hepa-
rinization was nor adjusted according to activated partial
thromboplastin time levels .
All patients gave informed consent to the protocol, which
was r.pproved by the Ethical Committee of the University of
Leuven .
Examinations. In each of the participating centers,
Holter monitoring was performed during the 1st 24 h .
Recordings were started as soon as possible after the initia-
tion of treatment. The same equipment (a two-channel
cassette tape recorder) was used in all patients, and the tapes
were centrally scanned for arrhythmias and ST changes
using computer analysis . Visual verification of all recorded
arrhythinias was performed by members of the electrocar-
diographic (ECG) core laboratory .
Enzymatic infarct size was determined from serial
measurements of alpha-hydroxybutyrate dehydrogenase
(HBDH) as reported previously (14) . Blood samples were
taken en admission and then every 12 h for 2 days and every
24 h until day 5. Central analysis was performed in Maas- .
tricht, The Netherlands. The cumulative release of alpha-
HBDH into plasma up to 72 h was used as a measure of
infarct size . In patients with incomplete data, this value was
estimated by extrapolation, eventually using locally deter-
mined serum aspartate aminotransferase activity .
Blood samples for the determination of fibrinogen and
tissue plasminogen activator antigen levels were taken be-
fore and at the end of the alteplase infusion . Analyses were
done centrally, according to standard methods (15,16). In
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addition, plasma concentrations of atenolol and alinidine
were determined 3 h after the first bolus administration
(17,18) .
During the 10 to 14 days after the onset of symptoms, all
patients were transferred to the University Hospital of
Leuven for cardiac catheterization, scintigraphic examina-
tion and exercise testing .
On the morning after discontinuation of the trial medica-
tion, a symptom-limited exercise test was performed with
the patient in the fasting state until a maximal heart rate of
200 beats/min minus age (in years) was obtained. A bicycle
ergometer (Ergomed 9301920) with stepwise increments of
10 W/min was used . A 12-lead ECG was recorded continu-
ously for >6 min into recovery or until changes stabilized .
Left ventriculography at rest was performed on the same
day with the aid of digital subtraction techniques . Digital
images of the left ventricle in the 30° right anterior oblique
position were acquired at 50 frames/s with a 256 x 256 x
10-bit pixel matrix as described previously (19) . Ten minutes
later, an infusion of isoproterenol was started at a rate oar
I
1g/min
and increased every 2 min by I pg until heart rate
was increased by 50% (maximal rate 120 beats/min) or until
clinical or ECG signs of ischemia or arrhythmias were noted .
A second digital-subtracted left ventriculogram was per-
formed in the same position at the end of the isoproterenol
infusion. All ventriculograms were stored on floppy disk .
Routine coronary angiography was performed afterward .
Finally, a radiopaque sphere of known dimensions was
filmed on completion of the procedures. Two experienced
angiographers identified the infarct-related vessel and as-
sessed paten-.y according to the TIMI classification (20) .
Left ventricular cavity borders were outlined semiautomat-
ically on the subtracted digital images at end-diastole and
end-systole. Volumes, global ejection fraction and regional
wall motion were calculated by the area-length (21) and
centerline (22,23) methods .
Scintigraphic infarct size was calculated from the extent
of the perfusion defects on planar and tomographic images
acquired 1 h after the injection of 20 mCi of technetium-99m
methoxyisobutylisonitrile (sestamibi). Three planar projec-
tions (anteroposterior and 45° and 70° left anterior oblique)
were stored on floppy disk and analyzed at Yale University .
The size of the myocardial perfusion defect was defined by
integrating the hypoperfused area under the lower limit
(mean - 2 SD of the circumferential profiles obtained from a
normal data base) and expressed as a proportion (x 100) of
the total potentially visualized normal myocardium. In this
way, a unitless value is obtained, reflecting both the extent
and severity of the perfusion defect (24) . Tomographic
images were obtained after transformation into axial slice- .
through the long axis of the left ventricle . A semiautomatic
delineation algorithm was used to calculate absolute infarct
size (in milliliters) and relative infarct size (as a percent of
the total perfused volume on the tomographic images) (25) .
A cutoff of 2 .5 SD of the reference value was used to
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discriminate between normally perfused and hypoperfused
:issue .
End points and statistical analysis. The primary end
points for comparing the effects of atenolol, alinidine or
placebo were global and regional left ventricular function as
measured by digital-subtracted left ventriculography at 10 to
14 days after the onset of symptoms and infarct size as
measured by scintigraphic or enzymatic methods . It was
thought that because stunned myocardium and nonischemic
myocardium adjacent to ischemic tissue respond to an
inotropic challenge (26-29), a comparison of the "contractile
reserve" after isoproterenol infusion would enhance the
chance of finding significant differences in left ventricular
function aaton„ the three treatment groups . In a previous
study (30), a 14% absolute increase in ejection fraction after
isoproterenol was observed in patients with successful
reperfusion . It was anticipated that global ejection fraction
during isoproterenol infusion would be 7% greater after
adjunctive treatment with atenolol or alinidine than after
placebo. To detect this difference with 80% power at the 5%
significance level, 69 analyzable stress angiograms per group
would be needed. For the power calculations a standard
deviation of 15 was used . Assuming missing or nonanalyz-
able angiograms in 25% of the patients, a total sample size of
276 patients was calculated.
Secondary end points were the incidence of major ar-
rhythmias during the 1st 24 h as measured by Halter moni-
toring, coronary artery patency and exercise capacity at 10
to 14 days and the occurrence of recurrent ischemia or
reinfarction during the hospital stay .
Standard statistical methods were used (31) . For cate-
goric data, the frequency and percent are given . For contin-
uous data, the mean value t SD are given for normally
distributed iz.easurements ; otherwise, median and 90%
range are reported. For categoric measurements, the three
treatment groups were compared by an extension of the
Fisher exact test. For continuous measurements, a one-way
analysis of variance (ANOVA) was performed if *he (possi-
bly transformed) data appeared to be normally distributed in
each group . Normality was assessed by the Shapiro-Wilk
test. If a normalizing transformation could not be found, the
Kruskal-Wallis test was used . In the parametric continuous
case, a Tukey Studentized range test was chosen to distin-
guish treatment groups in the event of a significant treatment
effect. In all other cases, pairwise significance tests com-
bined with a Bonferroni correction were employed . The
nominal significance level was fixed at 0 .05, but except for
the analysis of the primary end points, all tests had an
exploratory nature .
Remits
Baseline characteristics and adherence to assigned therapy .
From June 1988 to December 1990, 300 patients in 20
hospitals were randomized, of whom 8 (3 in the atenolol, l in
the alinidine and 4 in the placebo group) were excluded from
410
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Table 1
. Baseline Characteristics of the 292 Study Patients at Admission
the study ; 5 of these 8 patients were already receiving a
beta-blocker or calcium antagonist, 2 had had previous
bypass surgery and 1 patient had pericarditis . These eight
patients did not have major complications, and all were
discharged alive . Of the remaining 292 patients, 100 were
allocated to treatment with atenolol, 98 to alinidine and 94 to
placebo. At baseline, the three groups were similar with
respect to age, gender, incidence of previous infarction,
hypertension and diabetes mellitus (Table I) . Heart rate and
systolic blood pressure at entry were almost identical .
Of the 100 patients allocated to atenolol therapy, 70 (70%)
received the full intravenous dose of 10 mg and 29 (29%)
received only the initial dose of 5 mg . In one patient, no
intravenous atenolol could be given because of the develop-
ment of a contraindication after randomization . In the
alinidine group (n = 98), 80 patients (82%) received the full
intravenous dose of 40 mg and 16 patients (16%) received
20 mg. In two patients, no intravenous alinidine could be
given .
Effects on left ventricular fimciiaa and coronary potency .
In 235 (80%) of 292 patients (84 receiving atenolol, 78
receiving alinidine and 73 receiving placebo), the full digital
angiographic protocol (including the isoproterenol infusion)
was completed within 10 to 14 days
. In 12 patients (3
receiving atenolol, I receiving alinidine and 8 receiving
placebo), a digital left ventriculogram was performed at rest
but isoproterenol infusion was not started, mainly for clinical
reasons (recurrent chest pain or electrical instability)
. In 21
patients (9 receiving atenolol, 8 receiving alinidine and 4
receiving placebo), only a routine angiographic procedure
was performed within or after the 10 to 14 day period
because of clinical (recurrent chest pain or reinfarction) or
organizational problems
. The angiographic data of the latter
p = NS for all variables. Data are reported as median values (90% range) or number and percent of patients .
BP = blood pressure; HR = heart rate ; MI = myocardial infarction.
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group were not used for comparison of the effects on left
ventricular function . In 24 patients (8%) (4 receiving
atenolol, 11 receiving alinidine and 9 receiving placebo),
angiography was not performed because of patient refusal,
stroke or death .
No significant differences in global ejection fraction or
regional wall motion of the infarct or noninfarct zones at rest
or during isoproterenol infusion were found among the three
treatment groups (Table 2) .
The identification and patency assessment of the infarct-
related vessel in all patients who underwent coronary an-
giography within 10 to 14 days are given in Table 3 . The
percent involvement of right, left anterior descending and
left circumflex coronary arteries and the TIMI grades of the
affected vessel were very similar in the three groups (Table
3) .
Effects on enzymatic and scintigraphic Infarct size. Cumu-
lative release of alpha-HBDH into plasma up to 72 h could be
calculated in 290 patients (99%), either from complete data
(267 patients [91%]) or after extrapolation for missing alpha-
HBDH data (17 patients [6%]) or from locally determined
serum aspartate aminotransferase activity (6 patients [2%]) .
No significant differences were observed among the three
groups (Table 4) .
On both the planar and the tomographic technetium-99m
sestamibi images, quantification of the rest myocardial per-
fusion defects (infarct size) did not reveal a significant
difference among the three treatment groups (Table 4).
Effects on heart rate and arrhythmias during the 1st 24 h
and on exercise capacity at discharge
. The Holter ECG
monitor data are summarized in Table 5 . As expected, heart
rates were lower in the atenolol and alinidine groups . With
the doses used, atenolol slowed heart rate significantly more
Ateaolol Group
(n = 100)
Alinidine Group
(n = 98)
Placebo Group
(n = 94)
Age (yr)
59(39-70) 56(39-69) 57(40-68)
Male
80,8c% 86 ; % 80; 85%
HR (beats/min)
74 (55-I11) 70(52-120) 75(54-102)
Systolic HP (mm Hg) 130 (100-170)
130 (100-170) 135 (100-170)
Normal hemodynamic state
83 ; 83% 86; 86% 75 ; 80%
Previous MI 3 ; 3% 2 ; 2% 3 ; 3%
History of diabetes mellitus
4; 4% 8; 8%
5-,5%
Angina >4 weeks 15
; 15% 14; 14%
10 ; 11%
Third heart sound
3; 3% 3 ; 3% 9-.10%
Basilar pulmonary rates
< 10 cm 16; 16% II ; 11% 11 ; 12%
> 10 cm 0; 0% I ; 1% 1 ; 1%
Location of infarction
Anteriorlateral
33; 33%
3607% 3406%
Inferiodposterior 66; 66% 61-,62% 58; 62%
Not reported 1 ;1% 1 ; 1% 2 ; 2%
Minutes from onset of infarction 156 (85-300) 160 (70-275) 168 (72-330)
to start of treatment
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Table 2. Global and Regional Left Ventricular Function at Rest and During Infusion of Isoproterero!
than did alinidine ; maximal and minimal heart rates were on
average lower in the atenolol than in the alinidine group .
Sustained ventricular tachycardia and ventricular fibrillation
were recorded in a similar proportion of patients in the three
treatment groups. Maximal ST elevation and the number of
minutes with ST elevation >1 mm were not significantly
different in the three groups .
Exercise test results are given in Table 6 . Maximal work
load and total performed external work were significantly
greater in the atenolol group
. Hemodynamic responses at
maximal exercise were significantly lower for the beta-
blockergroup. In the alinidine group, pre-exercise heart rate
pressure was significantly lower than in the placebo group
.
For all other variah'es, the alinidine group did not differ
significantly from the placebo group . Typical angina during
Table 3. Infarct-Related Coronary Artery and Patency Rates
p = NS for all variables
. Data indicate number and percent of patients .
LAD = left anterior descending coronary artery; LCx = left circumflex
coronary artery ; RCA = right coronary artery ; TIMI = Thrombolysis in
Myocardial Infarction Trial .
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*Significantly different from placebo (p = 0
.009). Data are reported as median values (90% range) or mean value t SD . EDV = end-diastolic volume
; EF =
ejection fraction : ESV = end-systolic volume ; HR = heart rate : LVEDP = left ventricular end-diastolic pressure ; N, = number of chords with standard motion
<0; N, = number of chords with absolute motion :s0; SZi = sum of Zi of all chords in the hypokinetic tani!ory ; Zi = mean value of standardized motion of
chords lying in the most abnormally contracting 50%% (= central) and the remaining 50% (= peripheral) of the infarct zone and in the best contracting 50% of the
noninfarct zone .
the test occurred in only eight patients (two receiving
atenolol, four receiving alinidine and two receiving placebo) .
In four patients (none receiving atenolol, two receiving
alinidine and two receiving placebo), ventricular arrhyth-
mias were the reason for stopping the test . The target
maximal heart rate was attained in 13% of the patients
allocated to atenolol versus 31% of those allocated to alini-
dine (p = 0 .002) and 43% of those given placebo (p
0.0001) . A significantly greater proportion of the patients in
the atenolol group also reported fatigue at the end of the test
(67% vs. 47% in the alinidine group [p = 0 .006] and 39% in
the placebo group [p = 0 .00021) . Dyspnea was reported in a
similar proportion of patients in the three groups (16%, 15%
and 13%, respectively) .
Effects of atenolol and alinidine on coagulation srariables
and serum concentration . Fibrinogen levels before and 3 h
after the start of thrombolytic therapy were very similar in
the three groups . In addition, the tissue plasminogen activa-
tot- antigen levels did not differ significantly (Table 7)
.
Table 4 . Enzymatic and Scintigraphic Infarct Size
p = NS for all variables
. Da'a are reported as median values (90% range) .
Alpha-HBDH 72 = calculated cumulative release of alpha-hydroxybutyrate
dehydrogrnase into plasma up to 72 11 .
Atenolol Alinidine
Placebo
Rest
(n = 87)
Isoproterenol
(n = 84)
Rest
(n = 79)
Isoprotereno)
In = 78)
Rest
(n = 81)
Isoproterenol
(n = 73)
HR (beatslmin) 70 (50-102)8-
.
112 (94-124) 70(52-97)* 115 (90-135) 78 (55-105) 115 045-130)
EDV (ml) 114 ± 33 102 ± 34 113 t 41 106 ± 43 107 t 34 94 ± 26
ESV (ml) 49 ± 23 37 ± 23 49 ± 27 37 ± 25 47 ± 23 33 ± 19
LVEDP (mm Hg) 17 ± 8 10 ± 6 16±8 10±6 16±7 10±5
EF (0/0 57 ± 13 64 ± 16 58 ± 14 66 ± 14 57 ± 13 66 ± 15
Zi (SDichord) in
Central infarct zone
-1
.79 ± 0 .87
-1
.63 ± 1 .12
-1
.76 ± 0.98
-1
.46 ± 1 .23
-1
.71 ± 0.89
-1
.34 ± 1 .21
Peripheral infarct zone
-0
.92 ± 0 .90
-0
.67 ± 1 .17
-0
.91 ± 0.93
- 0
.43 ± 1 .11
-0
.92 ± 0 .94
-0
.47 t 1 .21
Noninfarct zone 0 .22 ± 1 .06 0 .94 ± 1 .29 0.21 ± 0.89 1 .20 ± 1 .22 0 .09 ± 1 .10 0.84 -t 1 .31
Extent of hypokinesia IN,) 30 (iO-57) 26(1-57) 28(7-57) 22(0-57) 2603-57) 22(0-55)
Severity of hypokinesia (SZi)
-44(140-4) -381151-0) -4](146-3) -30(168-0) -40(126-9) -29 (135-0)
Extent of akinesia (N_) O (C-26) 0(0-33) 010-37) 0(0-37) 0(0-29) 0(11-32)
Atenolol
(n = 96)
Alinidine
(n = 87)
Placebo
(n = 85)
Infarct-related vessel
RCA 54; 56% 47; 54% 47 ; 55%
LAD 32; 33% 28 ; 32% 30 ; 35%
LCx 10 ; 10% 12; 14% 8 ; 9%
Coronary patency by
TIM! classification
0 23; 24% 23; 26%
19 ; 22%
I 2-,2% 0; 0% 2 ; 2%
2 8 ; 8% 3 ; 3% 6; 7%
3 62; 65% 61-,70%
58 ; 68%
Undetermined 1 ; 1%
Atenolol Alinidi.ne Placebo
Alpha-HBDH 72 n = 99 n - 97 z= 94
(Ulliter) 527 (60-1,314)
464 (72-1,953) S52 (12-1,782)
Planar scintigraphic n = 90 n = 93
n = 87
defect size (unitless) 8(0-21)
7(0-21) 7(1-21)
Tomographic n = 83
n = 83 a = 78
scintigraphic score
Absolute (ml) 30(1-139)
22(2-138) 27(1-126)
Relative (%) 14(1-46)
11(1-51) 14(1-48)
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Table S
. Results of 24-Hour Hotter Monitoring
*,tTwo.group comparisons : *Significantly different from placebo
. tSig-
nificantly different from alinidine . *Three-group comparisons
: p values in the
final column
. Data are reported as median values (90% range) or number and
percent of pata'nts
. AV = atrioventricular ; HR = heart rate; VF - ventricular
fibrillation
; VT = ventricular tachycardia (sustained ventricular tachycardia)
was defined as a run of monomorphic or polymorphic consecutive ventricular
premature complexes at a rate >120 beats/min during >30 s or requiring
cardioversion.
Median (and 90% range) plasma concentrations of atenolol
and alinidine measured 3 h after the first intravenous admin-
istration were 105 (90% range 22 to 483) and 120 (90% range
30 to 300) ng/ml, respectively .
Effects on clinical events. Table 8 summarizes the clinical
course duri"e this hospital stay . Six patients died during the
hospital stay (four in the placebo group and one patient each
in the alinidine and atenolol groups) . In the placebo group,
two patients with inferior infarction died, one on day 9
because of cerebral bleeding diagnosed and confirmed by
computed tomography on day 2 after the start of thrombo-
lytic treatment and one with severe three-vessel disease who
died of multiple organ failure 6 weeks after bypass surgery
performed urgently because of recurrent chest and ventric-
ular fibrillation after coronary angiography . The other two
patients in the placebo group who died had anterior infarc-
tion ; one died of cardiac rupture on day 3, and another died
Table 6. Results of Exercise Testing
on the day 12 because of reinfarction followed by ventricular
fibrillation and asystole . The patient allocated to alinidine
had an acute anterior infarction and he had ventricular
fibrillation and asystole before study medication could be
started. Resuscitation efforts were unsuccessful ; no signs of
cardiac rupture were found at autopsy. The patient in the
atenolol group had an anterior infarction . Six hours after the
start of thrombolytic treatment, she had intracerebral bleed-
ing (confirmed by computed tomography) and died 7 days
later.
In addition to the two hemorrhagic strokes, two nonfatal
ischemic strokes were reported . The total incidence of
stroke in this trial was 1 .4% (4 of 292 patients) .
Recurrent chest pain and reinfarction occurred in a
similar proportion of patients in the three groups . Signifi-
cantly more patients allocated to atenolol had pulmonary
edema. As could be expected, a greater incidence of brady-
cardia and hypotension was reported in the atenolol and
alinidine groups. No significant differences among groups in
the incidence of major arrhythmias, emergency procedures
or bleeding complications were observed .
Discussion
Previous studies on the mechanism of action of beta-
blockers in acute myocardial infarction. The mechanism of
action of beta-blockers in acute myocardial infarction has
always been controversial despite extensive experimental
work and many clinical trials involving >50,000 patients
(32) . Most authors agree that treatment with beta-blockers,
when start;,d in the convalescent phase after infarction and
continued thereafter, reduces the late mortality rate by
preventing fatal arrhythmias and reinfarction . When given
intravenously within a few hours of the onset of infarction
and in the absence of thrombolytic therapy, beta blockers
have been shown to have a favorable effect on indirect
markers of infarct size (enzyme leakage and development of
Q waves) (33). However, there is no conclusive evidence
that early beta-blockade can prevent cell death and reduce
the extent of myocardial injury (34). Accordingly, the reduce
*,tTwo-group comparisons
: *Significantly different from placebo
. tSignificantly different from alinidine . tThree-
group comparisons
. Data are reported as median values (90%
range) . Abbreviations as in Table 1 .
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Atenolol
(n = 92)
Alinidine
(n = 94)
Placebo
(n = 87)
p Value*
Preexercise HR (beats/min)
66 (4990)*t 77 (52_104)*
88(61-128) 0.0001
Preexercise systolic BP (mm Hg)
113 (100-140)*f
120 (100-154) 120 (100-150) 0.03
Maximal work load (watts)
110 (60-150)*
90(50-150) 9000-140) 0.02
Total performed external work
(watts x min)
660 (210 •- t,200)`
450 (150-1,200) 450 (60-1,050) 0.02
Maximal HR (beats(min)
I11(89-148)*
139 (91-156) 140 (94-165) 0.0001
Maximal systolic BP (mm Hg)
160 (120200)*t 170 (115-220)
170 (130210) 0.03
Maximal rate-pressure pr.rduct
(beats/min x mm Hg) x 10
3
18 (12-29)*t
2303-31) 23(15-30) 0.0001
Atenolol
Alinidine
p
Placebo
Value*
n=90 n=80 n=79
Average HR (beatsimin)
66 (S1-80)* 68 (54-96)* 75 (59-98)
0.001
Maximal HR (beats/min) 102 (73-147)*t 108 (85-176)*
115 (93-195) 0.001
Minimal HR (beats/min) 44 (0-58)*t
47 (2-66)* 53(0-79) 0 .001
n=86
n=80 n=78
Maximal ST
elevation
(mm)
3.4 (1 .2-11) 3 .5 (1.3-9.5) 3.7 (0-8.9)
NS
Minutes with ST
elevation >1 mm
53 (0-1,324) 11(0-955)
77 (0-1,000) NS
n=83 n=85 n=81
Sustained VT and/or VF 4 ; 5%
I ; 1% 3 ; 4% NS
AV block (second or
third degree)
1 ; 1%
I ; 1% 0; 0% NS
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p = NS for all variables . Data are reported as median values (90% range)
. t-PA = tissue plasminogen activator.
tion in early mortality observed in the ISIS-1 study (35) has
been explained by the prevention of early cardiac rupture
and not by a limitation of infarct size. However, when given
in combination with thrombolytic therapy, such a beneficial
effect on the incidence of acute rupture was not observed by
the TIMI Investigators (8) . The latter study (8) also failed to
show beneficial effects on left ventricular function and total
mortality whereas less recurrent chest pain and reinfarction
were observed during the week 1 .
Possible advantages of specific bradycardlac agents .
Specific bradycardiac agents can attenuate stress-induced
ischemic dysfunction and improve regional perfusion by
increasing diastolic perfusion time without compromising
contractility of the nonischemic myocardium (10) . There-
fore, these agents might have a distinct advantage over
beta-blockers as adjunctive cardioprotective treatment in the
Table 8. Clinical Events During the Hospital Stay
acute phase of myocardial infarction because their use would
avoid the negative inotropic effects of beta-blockade .
Effects on infarct size, left ventricular function and ar-
rhythmias . The present study, which was designed before
the results of the TIMI 11-B trial were available, evaluated
the mechanisms that could explain the anticipated favorable
effects of a beta-blocker or a specific bradycardiac agent as
an adjunct to thrombolysis . The results indicate that the
early and continued administration of such agents does not
result in a greater limitation of infarct size . The lack of any
effect on predischarge left ventricular function as measured
by angiography at rest and during stress seems to be the
logical consequence and, for the atenolol arm of the study,
confirms the findings of the TIMI 11-B trial . Prevention of
reinfarction and the ability to reduce the incidence of serious
arrhythmias most likely explain the mortality rate reductions
*Two-group comparisons: significantly different from placebo
. tThree-group comparisons . Data indicate number
and percent of [patients
. Abbreviations as in Tables I and 5.
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Table 7 . Coagulation Variables
Atenolol
(n = 60)
Alinidinne
(n = 64)
Placebo
(n = 58)
Fibrinogen before treatment (g/liter)
2 .47
(0
.28-5 .97)
2
.63 (1 .47-4
.60) 2 .59 (0.28-4
.60)
Fibrinogen 3 h after start of thrombolysis (glliter) 1 .49
(0.28-3.1a) 1 .50 '0.28-3
.21) 1 .58 (0.28-3 .21)
I-PA antigen levels before treatment (mg/ml) 5.4
(2.0-12.0) 4 .9 (2 .1-14.0) 5 .5
(1 .4-83 .2)
t-PA antigen levels after 3 h (mg/ml) 489
(150-1 .663) 477 (66-2,512) 483
(92-2,400)
Event
Atanolol
In = 100)
Alinidine
(n = 98,
Placebo
(n = 94) p Values
Death 1 ; 1% 1 : 1%. 4 ; 4% NS
Reinfarction 9.9% 9.9% 10:11% NS
Recurrent chest pain 21 : 21% 17 ; 17% 20.21% NS
Pulmonary edema 6; 6%* 1 . 1% 0; 0 0 .02
Pericarditis
4 ; 4% 2 : 2% 3 ; 3% NS
Shock 1 .3% 1 . 1% 0; 0% NS
Systolic BP <90 mm Hg
25
; 25%* 29: 30%* 14 ; 15% 0 .04
Cardiac rupture (septum, free wall) 0:0% 1 ; 1%
1
: 1% NS
Rhythm disturbances as reported by the clinician
Bradycardia (HR <50 beats/min) 35 : 35%* 32 : 33%*
18:19% 0.03
2nd degree AV block
3
; 3%
2 ; 2% 3,3% NS
3rd degree AV block 6-.6% 3.3% 4.4% NS
Atrial fibrillation 8 ; 8% 3 ; 3%
4: 49 NS
Ventricular tachycardia 21 ; 21% 22 ; 22%
18 ; 19% NS
Ventricular fibrillation
2
; 2%
4;4% 3; 3% NS
Accelerated idioventricular rhythm 24
:24% 29; 30% 22 ; 23% NS
Emergency procedures
Angioplasty
1 :1% I : 1% 1
; 19i NS
Bypass surgery 2 ; 2% 2 : 2%
2; 2% NS
Electroshock
4
:4%
3.3% 5:5% NS
Mechanical ventilation
2; 2% 1 ; 1% 2: 2%
NS
Temporary pacemaker
2 ; 2% 2 : 2%
1 ; 1% NS
Bleeding complications requiring transfusion
2 ; 2% 1 : 1% 1 : 1%
NS
Stroke
Hemorrhagic
1 ; 1%
0: 0% 1 ; 1%
NS
Ischemic 0 ; 0%
1 ; 1% I ; I%
NS
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observed with long-term use of beta-blockers after infarc-
tion. Whether antiarrhythmic mechanisms also play a part in
the acute phase of myocardial infarction treated with throm-
bolysis is less well established. In the present study, 24-h
Hotter monitoring immediately after the start of treatment
did not reveal significant differences in the frequency and
ECG presentation of serious arrhythmias . Also, the reported
clinical incidence rates of ventricular tachycardia and ven-
tricular fibrillation during the hospital phase were similar in
the different treatment groups. These results are in full
agreement with those reported by the TIMI investigators and
indicate that early beta-blockade in combination with throm-
bolytic therapy does not reduce the incidence of major
arrhythmias in the early phase of infarction when results are
compared with those of thrombolytic therapy alone . Like-
wise, although antiarrhythmic properties have been attrib-
uted to alinidine (36), they do not appear to be clinically
relevant in the acute phase of myocardial infarction treated
with thrombolysis .
Effects on the flbrinolytie system. Beta-blockers may alter
the fibrinolytic efficacy of tissue plasminogen activator
through a reduction in hepatic blood flow and plasma clear-
ance rates or through changes in prostacyclin formation (37).
The lack of any significant effect on the plasma levels of
tissue plasminogen activator antigen and fibrinogen (also
found in TIMI II-B) on the duration of the ST elevations
during the 1st 24 h (Hotter monitoring) and on coronary
patency at late angiography suggests that beta!-blockade
with atenolol does not induce a clinically relevant change in
the thrombolytic efficacy of tissue plasminogen activator
when given as a thrombolytic agent . The same seems to be
true for the concomitant administration of alinidine . How-
ever, because early coronary angiograms were not obtained
in this study, these results can only be considered as indirect
evidence. The overall patency rates at late angiography were
rather low despite the continuous administration of heparin
throughout the hospital stay, a result that might be attributed
to the lack of aspirin .
Effects on clinical outcome and exercise capacity . In con-
trast to the findings of the TIMI 1-B trial, we did not observe
a reduction in the incidence of recurrent chest pain or
reinfaretion . The in-hospital reinfarction rate in the present
study was rather high (9% to 11%) comparer' with that in
TIMI 1-B (3% to 5%) . This might be the result of the
absence of aspirin and the less frequent performance of
angioplasty in our study. As in TIMI II-B, the in-hospital
mortality rate was very low
. Of notice, no cardiac deaths
were observed in patients who received atenolol or alinidine :
the patient allocated to alinidine therapy died before the drug
could be administered and the cause of death in the patient
from the atenolol group was cerebral bleeding
. In TIMI II-B,
the incidence of death or reinfarction within 6 weeks among
patients treated within 2 h of symptom onset was signifi-
cantly lower than in the delayed therapy group, but the
difference disappeared at 1 year follow-up
. Because of the
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smaller number of patients, no analysis of prespecified
subgroups was performed in the present trial .
Patients allocated to atenolol therapy achieved a signifi-
cantly higher external work load at the predischarge exercise
test . This was not due to better preservation of left ventric-
ular function but to residual beta-adrenoreceptor blocking
activity at the time of the test as indicated by the lower
rate-pressure product at peak exercise and the smaller
proportion of patients who attained the target maximal heart
rate.
The early intravenous and continued oral administration
of atenolol or alinidine in combination with alteplase is safe
if no contraindications for such medication are present on
admission. Nevertheless, a word of caution is needed be-
cause despite the absence of contraindications to beta-
blocking therapy and an only moderate infarct size on
average, a 6% incidence rate of nonfatal pulmonary edema
was observed in the atenolol group . An excess incidence of
left heart failure was not found with alinidine, indicating the
absence of a significant negative inotropic effect .
Limitations of the study . For obvious reasons, the num-
ber of patients who can enter a sophisticated mechanistic
study with central performance and analysis of all technical
examinations is limited. Thus, the relatively small sample
size is the major limitation of this study . The study lacks
sufficient power to detect small differences in left ventricular
function or infarct size. However, in view of the present data
and the results of TIMI Il-B, it is very unlikely that the
anticipated clinical benefit of early beta-blockade can be
attributed to a further reduction in infarct size and better
preservation of left ventricular function . The same appears
to be true for the specific bradycardiac agent alinidine .
Recent studies have shown that optimal conjunctive
antithrombotic treatment with alteplase should include aspi-
rin (38) and early intravenous heparin (39) for ?48 h with
frequent adjustments of the heparin dose according to the
activated partial thromplastin times . The lack of aspirin and
the administration of a fixed dose of heparin in the present
trial might have influenced some of the results (for example,
overall patency rates) . However, because adjunctive anti-
thrombotic treatment was the same in the three groups, a
significant effect an the primary end points of the study is
unlikely .
Conclusions. Should beta-blockers or specific bradycar-
diac agents be given in the acute phase of myocardial
infarction? If beta-blockers given concomitantly with
thrombelytic agents do not further reduce infarct size or
further improve predischarge left ventricular function and if
they do not favorably affect the efficacy of thrombolytic
agents, electrical stability or reinfarction rate, should they be
given routinely in the acute phase of myocardial infarction?
From the results of the present study and those of the TIMI
II-B trial, it is obvious that the answer is no . Theoretically,
however, it is not excluded that these agents, when given
together with thrombolysis, further reduce mortality by
mechanisms that could not be detected in this study or in
JACC Vol . 22, No. 2
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TIMI II-B because of the relatively small number of patients .
Such mechanisms could include the prevention of cardiac
rupture as demonstrated in patients not treated with throm-
bolytic agents (35) (although the TIMI 11-B data do not
support this hypothesis), an earlier (but noi, greater) recov-
ery of left ventricular function as shown in animals (4) by
which some patients with a very large infarction might be
saved in the first days (this hypothesis also is not supported
by TIMI II-B data), or the prevention of fatal cerebral
bleeding by a protective effect on the cerebral circulation (a
lower incidence of intracranial hemorrhage was observed in
TIMI II-B but not in the GISSI-2/International Trial [40]) .
It is also possible that prevention of fatal ventricular
arrhythmias in the acute phase of infarction is better
achieved by use of a non-beta, -selective blocker as sug-
gested by Norris et al . (41). Acute intravenous beta-blockade
with nonselective agents in combination with thrombolysis
has never been tested in randomized clinical trials . Thus, to
convincingly demonstrate a possible benefit of early beta-
blockade as adjunctive treatment to thrombolysis a large
mortality trial might be considered . However, these patients
already have a low risk profile in light of the absence of
contraindications to intravenous beta-blockade ; therefore,
because the detectable differences in clinical outcome would
be very small and thus of questionable clinical relevance,
such a trial might involve tens of thousands of patients and
provide little new information .
From this study in a limited nu .nber of patients, specific
bradycardiac agents such as alinidine appear not to be
superior to beta-blockers as adjuvant cardioprotective treat-
ment. The lack of a clinically demonstrable negative iso-
tropic effect might constitute an advantage over beta-
blockers in the early phase of a myocardial infarction when
heart rate reduction is indicated .
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Appendix
Participating Centers and Investigators
The following centers and investigators collaborated
. *Indicates members of
the Steering Committee, Unless otherwise indicated, all institutions
listed are
in Belgium .
Centers. University Hospital Gasthuisberg, Leuven (H
. De Geest .*
F . Van de Werf,* T . Brzostek, L
. Janssens, K . Ghoos ; St
. Dimpna Hospital,
Geel (J . Schurmans);
Andre Dum ont Hospital, Genk-Waterschei (W . Van
Mieghem, Ph
. De Vusser) ; St . Elisabeth Hospital, Turnhout (H
. Lesseliers*)
;
H. Hart Hospital, Roeselare (R
. Beeuwsaert, D. Clement)
; Onze-Lieve-
Vrouw Hospital, Tongeren (F. Gielen) ; St
. Jozef Hospital, St. Truiden
(H . Robijns, J
. Beckers)
:
St. Rembert Hospital, Torhoat (Ph
. Van Iseghem) ;
St. Niklaas Hospital, Kortryk
(Ph . Dejaegher) ; St
. Jozef Hospital, Oostende
(R . Stroobandt, G. Holvoel) ;
St . Norbertus Hospital,
Duffel
(U .
Van
Walleghem)
; Onze-Lieve-Vrouw Hospital, Mechelen (J
. Beys) ; St . Lucas
Hospital, Brugge (S. Dotremont, J . Van de Meulebroucke); H
. Hart Hospital,
Neerpelt (A. Van Dorpe*);
Hospital De Pelikaan, Temse (D . Koen€ges);
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H. Familie Hospital, Reet IA . Missotten) ;
St . Elisabeth Hospital, Herentals
(S . De Schepper) ; St
. Andries Hospital, Tielt (B . Carlier) ; St . Vinc,rrjius
Hospital, Gent (P. Cambier) : St
. Elisabeth Hospital, Lier (J . Goovaerts) .
Angiographic Core Laboratory .
Departmen, of Cardiology, University of
Leuven (T Brzostek . F. `pan de Werf, L . Janssens, F
. Sta,u 'n, J . De Cock) .
Radionuclide Core
i_.-oratories
University of Leuven (M . De Roe,
L. Mortelmans)
and Yale University, New Haven, Connecticut (F . Wackers)
Core Laboratory for Enzyme Determination. University ofMaastricht, The
Netherlands (WT Hermens, GM Willems)
EIec rocardiographic Core Laboratory. Department of Cardiology, Uni-
versity of Leuven (H . HeidbUchel . A. Ballet, S
. Vanneste, J . Tack, H. Ector)
Coagulation Core Laboratory.
Center for Thrombosis and Hemostasis,
University of Leuven (D. Collen, R. Lgnen)
Data Coordination and Statistical Assistance .
Orda-B, Haasrode (B . Ger-
monprez, H. Van Gilbergen), Biostatistical Center, University of Leuven
(E
. Lesaifre. I . Scheys, C . Lauwereyns) and Department of
Cardiology,
University of Leuven (A .
De Clerck, K . Verberckmoes, A . Meuris)
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